Copyright: Immunotech Applied Science Limited   京ICP备19008112号-1    

Page view

TCR-T Cell Products Pipeline

Affiliate classification

TCR-T cell therapy uses genetic engineering methods to transfer TCR sequences that can specifically bind to target antigens into T cells derived from peripheral blood of patients, and then reinfuse the transformed T cells into patients to make them specific Recognize and kill tumour cells expressing antigen, so as to achieve the purpose of tumour treatment. At present, the company has a number of TCR-T cell products candidates under pre-clinical studies. We have a number of TCR-T cell product candidates under pre-clinical studies, with the relevant target antigens including the cancer-testis antigen or cancer-placental antigen such as NY-ESO-1, and antigens derived from viruses such as EBV and HPV. The indications of TCR-T product include clear renal cell carcinoma, CMV、EBV infection after hematopoietic stem cell transplantation, etc.

Corresponding parameter set not found, please add it in property template of background